Practical Management of CD30+ Lymphoproliferative Disorders

• Autores: Lauren C. Hughey
• Localización: Dermatologic clinics, ISSN 0733-8635, Vol. 33, Nº. 4, 2015 (Ejemplar dedicado a: Cutaneous Lymphoma), págs. 819-833
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Primary cutaneous CD30+ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30+ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30+ disorders and offers practical pearls to aid in choosing an appropriate regimen.